Advancing a New Standard in Regenerative Urology
OhhMed Medical is building a clinically validated, commercially scalable platform to address significant unmet needs in men’s health.
Our proprietary radiofrequency (RF) therapy system, Vertica®, is designed to treat the biological causes of erectile dysfunction, Peyronie’s Disease, and post-prostatectomy complications – without drugs or surgery.
With regulatory clearances in the UK, EU and Australia and a pivotal FDA trial underway, OhhMed is positioned to lead the global transition toward restorative, non-invasive urology.
OhhMed is targeting three large, under-served markets with limited long-term treatment options:
Erectile Dysfunction (ED)
- Affects over 300 million men globally
- 50% of men aged 40–70 experience ED
- Global market projected at $4.9B by 2030
Post-Prostatectomy Rehabilitation
- ~500,000 radical prostatectomies annually, 80% result in ED
- Supports pre-operative conditioning and functional recovery post-surgery
Peyronie’s Disease
- Impacts up to 60 million men
- Global market projected to reach $2.68B by 2033
Growth Strategy
OhhMed’s strategic roadmap focuses on building commercial momentum, expanding indications, and entering new markets through clinical validation and strong channel execution.
2025
- Scale direct-to-consumer home-use device sales in the UK and Israel
- Expand prescriber support and educational outreach
- Collect and publish real-world outcome data
2026
- Launch Vertica®Pro in the UK and EU
- Establish clinic partnerships delivering structured prehabilitation and rehabilitation programmes
- Initiate broader clinic network activation
2027
- Secure FDA clearance and launch in the U.S. market
- Initiate reimbursement discussions and expand sales and medical affairs infrastructure
2028–2029
- Expand Vertica® indications to Peyronie’s Disease and post-prostatectomy recovery
- Scale across urology and men’s health providers
- Integrate platform into reimbursed care pathways
Business Model
- Clinic: Capital equipment sales (Vertica®Pro)
- Recurring revenue: Disposable single-use and single-patient-use applicators
- Digital tools: Optional subscriptions for clinical dashboards and patient-reported outcome tracking
- Clinic-integrated pathways: Vertica®Plus supports pre-hab, follow-up and hybrid care models
- Consumer: Home-use device sales (Vertica®, Vertica®Plus)
Future applications
Future applications are currently in development, including dedicated protocols and applicators for post-surgical rehabilitation, Peyronie’s Disease, and urinary flow restoration.
These advancements will expand Vertica® Pro’s value across a wider spectrum of male pelvic health needs.